| Nov 15 |
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024
|
| Nov 13 |
89bio drops 2%, prices $125M stock offering
|
| Nov 13 |
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants
|
| Nov 12 |
89bio announces proposed underwritten public offering of common stock and pre-funded warrants
|
| Nov 12 |
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
|
| Nov 8 |
89bio GAAP EPS of -$1.39 misses by $0.78
|
| Nov 7 |
89bio Reports Third Quarter 2024 Financial Results and Corporate Updates
|
| Nov 5 |
89bio to Participate in the UBS Global Healthcare Conference
|
| Nov 2 |
Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH
|
| Nov 1 |
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
|
